{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T00:15:59Z","timestamp":1791850559166,"version":"4.3.4"},"reference-count":64,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2015,6,1]],"date-time":"2015-06-01T00:00:00Z","timestamp":1433116800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","theclinics.com","pediatric.theclinics.com","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pediatric Clinics of North America"],"published-print":{"date-parts":[[2015,6]]},"DOI":"10.1016\/j.pcl.2015.03.005","type":"journal-article","created":{"date-parts":[[2015,4,11]],"date-time":"2015-04-11T23:55:17Z","timestamp":1428796517000},"page":"633-648","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":104,"title":["Tuberous Sclerosis Complex"],"prefix":"10.1016","volume":"62","author":[{"suffix":"Jr.","given":"Francis J.","family":"DiMario","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mustafa","family":"Sahin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Darius","family":"Ebrahimi-Fakhari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.pcl.2015.03.005_bib1","series-title":"The tuberous sclerosis complex","year":"1999"},{"key":"10.1016\/j.pcl.2015.03.005_bib2","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1001\/archneur.57.5.662","article-title":"National Institutes of Health consensus conference: tuberous sclerosis complex","volume":"57","author":"Hyman","year":"2000","journal-title":"Arch Neurol"},{"key":"10.1016\/j.pcl.2015.03.005_bib3","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1016\/0092-8674(93)90618-Z","article-title":"Identification and characterization of the tuberous sclerosis gene on chromosome 16","volume":"75","author":"European Chromosome 16 Tuberous Sclerosis Consortium","year":"1993","journal-title":"Cell"},{"key":"10.1016\/j.pcl.2015.03.005_bib4","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1126\/science.277.5327.805","article-title":"Identification of the tuberous sclerosis gene TSC1 on chromosome 9q34","volume":"277","author":"van Slegtenhorst","year":"1997","journal-title":"Science"},{"key":"10.1016\/j.pcl.2015.03.005_bib5","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1086\/316951","article-title":"Mutational analysis in a cohort of 224 tuberous sclerosis patients indicates increased severity of TSC2, compared to TSC1, disease in multiple organs","volume":"68","author":"Dabora","year":"2001","journal-title":"Am J Hum Genet"},{"key":"10.1016\/j.pcl.2015.03.005_bib6","first-page":"345","article-title":"Molecular genetic advances in tuberous sclerosis","volume":"62","author":"Cheadle","year":"2000","journal-title":"Hum Genet"},{"key":"10.1016\/j.pcl.2015.03.005_bib7","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1097\/GIM.0b013e31803068c7","article-title":"Genotype\/phenotype correlation in 325 individuals referred for a diagnosis of tuberous sclerosis complex in the United States","volume":"9","author":"Au","year":"2007","journal-title":"Genet Med"},{"key":"10.1016\/j.pcl.2015.03.005_bib8","doi-asserted-by":"crossref","first-page":"13571","DOI":"10.1073\/pnas.202476899","article-title":"Tuberous sclerosis complex-1 and -2 gene products function together to inhibit mammalian target of rapamycin (mTOR)-mediated downstream signaling","volume":"99","author":"Tee","year":"2002","journal-title":"Proc Natl Acad Sci U\u00a0S\u00a0A"},{"key":"10.1016\/j.pcl.2015.03.005_bib9","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1081\/CNV-200027144","article-title":"The tuberous sclerosis complex genes in tumor development","volume":"22","author":"Mak","year":"2004","journal-title":"Cancer Invest"},{"issue":"4","key":"10.1016\/j.pcl.2015.03.005_bib10","first-page":"535","article-title":"TBC1D7 is a third subunit of the TSC1-TSC2 complex upstream of mTORC1","volume":"47","author":"Dibble","year":"2012","journal-title":"Mol Cell Biol"},{"issue":"9","key":"10.1016\/j.pcl.2015.03.005_bib11","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1038\/ncb847","article-title":"Tsc tumour suppressor proteins antagonize amino-acid-TOR signalling","volume":"4","author":"Gao","year":"2002","journal-title":"Nat Cell Biol"},{"issue":"9","key":"10.1016\/j.pcl.2015.03.005_bib12","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1038\/ncb839","article-title":"TSC2 is phosphorylated and inhibited by Akt and suppresses mTOR signalling","volume":"4","author":"Inoki","year":"2002","journal-title":"Nat Cell Biol"},{"issue":"10","key":"10.1016\/j.pcl.2015.03.005_bib13","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1007\/s00109-013-1057-6","article-title":"mTOR and regulation of energy homeostasis in humans","volume":"91","author":"Mannaa","year":"2013","journal-title":"J\u00a0Mol Med"},{"issue":"2","key":"10.1016\/j.pcl.2015.03.005_bib14","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1016\/j.cell.2012.03.017","article-title":"mTOR signaling in growth control and disease","volume":"149","author":"Laplante","year":"2012","journal-title":"Cell"},{"issue":"2","key":"10.1016\/j.pcl.2015.03.005_bib15","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/j.neuron.2014.09.034","article-title":"The neurology of mTOR","volume":"84","author":"Lipton","year":"2014","journal-title":"Neuron"},{"issue":"1\u20132","key":"10.1016\/j.pcl.2015.03.005_bib16","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1038\/pr.2013.185","article-title":"Emerging role of autophagy in pediatric neurodegenerative and neurometabolic diseases","volume":"75","author":"Ebrahimi-Fakhari","year":"2014","journal-title":"Pediatr Res"},{"issue":"2","key":"10.1016\/j.pcl.2015.03.005_bib17","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1007\/s00401-012-1004-6","article-title":"Protein degradation pathways in Parkinson's disease: curse or blessing","volume":"124","author":"Ebrahimi-Fakhari","year":"2012","journal-title":"Acta Neuropathol"},{"key":"10.1016\/j.pcl.2015.03.005_bib18","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.gde.2014.04.003","article-title":"Autophagy and human disease: emerging themes","volume":"26C","author":"Schneider","year":"2014","journal-title":"Curr Opin Genet Dev"},{"issue":"1","key":"10.1016\/j.pcl.2015.03.005_bib19","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/0092-8674(94)90570-3","article-title":"RAFT1: a mammalian protein that binds to FKBP12 in a rapamycin-dependent fashion and is homologous to yeast TORs","volume":"78","author":"Sabatini","year":"1994","journal-title":"Cell"},{"issue":"6483","key":"10.1016\/j.pcl.2015.03.005_bib20","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1038\/369756a0","article-title":"A\u00a0mammalian protein targeted by G1-arresting rapamycin-receptor complex","volume":"369","author":"Brown","year":"1994","journal-title":"Nature"},{"issue":"2","key":"10.1016\/j.pcl.2015.03.005_bib21","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1074\/jbc.270.2.815","article-title":"Isolation of a protein target of the FKBP12-rapamycin complex in mammalian cells","volume":"270","author":"Sabers","year":"1995","journal-title":"J\u00a0Biol Chem"},{"issue":"5","key":"10.1016\/j.pcl.2015.03.005_bib22","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1016\/j.conb.2012.04.008","article-title":"Targeted treatment trials for tuberous sclerosis and autism: no longer a dream","volume":"22","author":"Sahin","year":"2012","journal-title":"Curr Opin Neurobiol"},{"issue":"4","key":"10.1016\/j.pcl.2015.03.005_bib23","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1016\/j.pediatrneurol.2013.12.002","article-title":"Mechanism-based treatment in tuberous sclerosis complex","volume":"50","author":"Julich","year":"2014","journal-title":"Pediatr Neurol"},{"issue":"5","key":"10.1016\/j.pcl.2015.03.005_bib24","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/j.pediatrneurol.2012.02.015","article-title":"Emerging treatments in the management of tuberous sclerosis complex","volume":"46","author":"Kohrman","year":"2012","journal-title":"Pediatr Neurol"},{"key":"10.1016\/j.pcl.2015.03.005_bib25","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/j.pediatrneurol.2013.08.001","article-title":"Tuberous Sclerosis Complex Diagnostic Criteria Update: Recommendations of the 2012 International Tuberous Sclerosis Complex Consensus Conference","volume":"49","author":"Northrup","year":"2013","journal-title":"Pediatr Neurol"},{"key":"10.1016\/j.pcl.2015.03.005_bib26","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1007\/s00787-005-0443-1","article-title":"TSC Behaviour Consensus Panel. Consensus clinical guidelines for the assessment of cognitive and behavioural problems in tuberous sclerosis","volume":"14","author":"de Vries","year":"2005","journal-title":"Eur Child Adolesc Psychiatry"},{"key":"10.1016\/j.pcl.2015.03.005_bib27","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/j.pediatrneurol.2013.08.002","article-title":"Tuberous sclerosis complex surveillance and management: recommendations of the 2012 International Tuberous Sclerosis Complex Consensus Conference","volume":"49","author":"Kruger","year":"2013","journal-title":"Pediatr Neurol"},{"issue":"1","key":"10.1016\/j.pcl.2015.03.005_bib28","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1227\/01.NEU.0000249216.19591.5D","article-title":"Subependymal giant-cell astrocytomas in pediatric tuberous sclerosis disease: when should we operate?","volume":"60","author":"de Ribaupierre","year":"2007","journal-title":"Neurosurgery"},{"issue":"2","key":"10.1016\/j.pcl.2015.03.005_bib29","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1007\/s12519-010-0025-2","article-title":"Management of subependymal giant cell tumors in tuberous sclerosis complex: the neurosurgeon's perspective","volume":"6","author":"Berhouma","year":"2010","journal-title":"World J Pediatr"},{"issue":"9861","key":"10.1016\/j.pcl.2015.03.005_bib30","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/S0140-6736(12)61134-9","article-title":"Efficacy and safety of everolimus for subependymal giant cell astrocytomas associated with tuberous sclerosis complex (EXIST-1): a multicentre, randomised, placebo-controlled phase 3 trial","volume":"381","author":"Franz","year":"2013","journal-title":"Lancet"},{"issue":"19","key":"10.1016\/j.pcl.2015.03.005_bib31","doi-asserted-by":"crossref","first-page":"1801","DOI":"10.1056\/NEJMoa1001671","article-title":"Everolimus for subependymal giant-cell astrocytomas in tuberous sclerosis","volume":"363","author":"Krueger","year":"2010","journal-title":"N\u00a0Engl J Med"},{"issue":"6","key":"10.1016\/j.pcl.2015.03.005_bib32","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1212\/WNL.0b013e3182815428","article-title":"Everolimus long-term safety and efficacy in subependymal giant cell astrocytoma","volume":"80","author":"Krueger","year":"2013","journal-title":"Neurology"},{"issue":"7","key":"10.1016\/j.pcl.2015.03.005_bib33","doi-asserted-by":"crossref","first-page":"1236","DOI":"10.1111\/j.1528-1167.2009.02474.x","article-title":"The natural history of epilepsy in tuberous sclerosis complex","volume":"51","author":"Chu-Shore","year":"2010","journal-title":"Epilepsia"},{"issue":"7","key":"10.1016\/j.pcl.2015.03.005_bib34","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.1111\/j.1528-1167.2008.01589.x","article-title":"Vigabatrin in the treatment of childhood epilepsy: a retrospective chart review of efficacy and safety profile","volume":"49","author":"Camposano","year":"2008","journal-title":"Epilepsia"},{"issue":"2","key":"10.1016\/j.pcl.2015.03.005_bib35","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/S0920-1211(96)01006-6","article-title":"Randomized trial comparing vigabatrin and hydrocortisone in infantile spasms due to tuberous sclerosis","volume":"26","author":"Chiron","year":"1997","journal-title":"Epilepsy Res"},{"issue":"11","key":"10.1016\/j.pcl.2015.03.005_bib36","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1177\/0883073810365103","article-title":"Vigabatrin for the treatment of infantile spasms: final report of a randomized trial","volume":"25","author":"Elterman","year":"2010","journal-title":"J\u00a0Child Neurol"},{"issue":"6","key":"10.1016\/j.pcl.2015.03.005_bib37","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/j.ejpn.2007.03.010","article-title":"Current role of vigabatrin in infantile spasms","volume":"11","author":"Parisi","year":"2007","journal-title":"Eur J Paediatr Neurol"},{"issue":"2","key":"10.1016\/j.pcl.2015.03.005_bib38","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/j.ejpn.2009.03.003","article-title":"Early control of seizures improves long-term outcome in children with tuberous sclerosis complex","volume":"14","author":"Bombardieri","year":"2010","journal-title":"Eur J Paediatr Neurol"},{"issue":"5","key":"10.1016\/j.pcl.2015.03.005_bib39","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1016\/j.ejpn.2011.03.010","article-title":"Antiepileptic treatment before the onset of seizures reduces epilepsy severity and risk of mental retardation in infants with tuberous sclerosis complex","volume":"15","author":"Jozwiak","year":"2011","journal-title":"Eur J Paediatr Neurol"},{"issue":"6","key":"10.1016\/j.pcl.2015.03.005_bib40","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD001770.pub3","article-title":"Treatment of infantile spasms","author":"Hancock","year":"2013","journal-title":"Cochrane Database Syst Rev"},{"issue":"6","key":"10.1016\/j.pcl.2015.03.005_bib41","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1016\/j.ejpn.2012.05.004","article-title":"Management of epilepsy associated with tuberous sclerosis complex (TSC): clinical recommendations","volume":"16","author":"Curatolo","year":"2012","journal-title":"Eur J Paediatr Neurol"},{"issue":"3","key":"10.1016\/j.pcl.2015.03.005_bib42","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.ejpn.2006.03.001","article-title":"The effects of the ketogenic diet in refractory partial seizures with reference to tuberous sclerosis","volume":"10","author":"Coppola","year":"2006","journal-title":"Eur J Paediatr Neurol"},{"issue":"10","key":"10.1016\/j.pcl.2015.03.005_bib43","doi-asserted-by":"crossref","first-page":"1684","DOI":"10.1111\/j.1528-1167.2005.00266.x","article-title":"Tuberous sclerosis complex and the ketogenic diet","volume":"46","author":"Kossoff","year":"2005","journal-title":"Epilepsia"},{"issue":"1\u20132","key":"10.1016\/j.pcl.2015.03.005_bib44","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/j.eplepsyres.2011.10.021","article-title":"Low glycemic index treatment for epilepsy in tuberous sclerosis complex","volume":"99","author":"Larson","year":"2012","journal-title":"Epilepsy Res"},{"issue":"4","key":"10.1016\/j.pcl.2015.03.005_bib45","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1177\/0883073808324535","article-title":"Rapamycin reduces seizure frequency in tuberous sclerosis complex","volume":"24","author":"Muncy","year":"2009","journal-title":"J\u00a0Child Neurol"},{"issue":"6","key":"10.1016\/j.pcl.2015.03.005_bib46","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1016\/j.ejpn.2013.06.002","article-title":"Everolimus in tuberous sclerosis patients with intractable epilepsy: a treatment option?","volume":"17","author":"Wiegand","year":"2013","journal-title":"Eur J Paediatr Neurol"},{"issue":"5","key":"10.1016\/j.pcl.2015.03.005_bib47","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1002\/ana.23960","article-title":"Everolimus treatment of refractory epilepsy in tuberous sclerosis complex","volume":"74","author":"Krueger","year":"2013","journal-title":"Ann Neurol"},{"issue":"2","key":"10.1016\/j.pcl.2015.03.005_bib48","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1097\/WCO.0b013e32834451c4","article-title":"Mechanisms of neurocognitive dysfunction and therapeutic considerations in tuberous sclerosis complex","volume":"24","author":"Tsai","year":"2011","journal-title":"Curr Opin Neurol"},{"issue":"10","key":"10.1016\/j.pcl.2015.03.005_bib49","doi-asserted-by":"crossref","first-page":"1777","DOI":"10.1038\/sj.ki.5001853","article-title":"Renal manifestations of tuberous sclerosis complex: incidence, prognosis, and predictive factors","volume":"70","author":"Rakowski","year":"2006","journal-title":"Kidney Int"},{"issue":"1","key":"10.1016\/j.pcl.2015.03.005_bib50","doi-asserted-by":"crossref","first-page":"e15","DOI":"10.1159\/000320891","article-title":"Tuberous sclerosis complex renal disease","volume":"118","author":"Dixon","year":"2011","journal-title":"Nephron Exp Nephrol"},{"issue":"9869","key":"10.1016\/j.pcl.2015.03.005_bib51","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1016\/S0140-6736(12)61767-X","article-title":"Everolimus for angiomyolipoma associated with tuberous sclerosis complex or sporadic lymphangioleiomyomatosis (EXIST-2): a multicentre, randomised, double-blind, placebo-controlled trial","volume":"381","author":"Bissler","year":"2013","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.pcl.2015.03.005_bib52","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1056\/NEJMoa063564","article-title":"Sirolimus for angiomyolipoma in tuberous sclerosis complex or lymphangioleiomyomatosis","volume":"358","author":"Bissler","year":"2008","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.pcl.2015.03.005_bib53","doi-asserted-by":"crossref","first-page":"e23379","DOI":"10.1371\/journal.pone.0023379","article-title":"Multicenter phase 2 trial of sirolimus for tuberous sclerosis: kidney angiomyolipomas and other tumors regress and VEGF- D levels decrease","volume":"6","author":"Dabora","year":"2011","journal-title":"PLoS One"},{"issue":"12","key":"10.1016\/j.pcl.2015.03.005_bib54","doi-asserted-by":"crossref","first-page":"4071","DOI":"10.1158\/1078-0432.CCR-11-0445","article-title":"Sirolimus therapy for angiomyolipoma in tuberous sclerosis and sporadic lymphangioleiomyomatosis: a phase 2 trial","volume":"17","author":"Davies","year":"2011","journal-title":"Clin Cancer Res"},{"issue":"6","key":"10.1016\/j.pcl.2015.03.005_bib55","doi-asserted-by":"crossref","first-page":"1657","DOI":"10.1007\/s11255-012-0292-z","article-title":"Nephron-sparing resection of angiomyolipoma after sirolimus pretreatment in patients with tuberous sclerosis","volume":"44","author":"Staehler","year":"2012","journal-title":"Int Urol Nephrol"},{"issue":"3","key":"10.1016\/j.pcl.2015.03.005_bib56","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/j.resinv.2013.03.002","article-title":"Efficacy and safety of low-dose sirolimus for treatment of lymphangioleiomyomatosis","volume":"51","author":"Ando","year":"2013","journal-title":"Respir Investig"},{"issue":"12","key":"10.1016\/j.pcl.2015.03.005_bib57","doi-asserted-by":"crossref","first-page":"797","DOI":"10.7326\/0003-4819-154-12-201106210-00007","article-title":"Changes in lung function and chylous effusions in patients with lymphangioleiomyomatosis treated with sirolimus","volume":"154","author":"Taveira-DaSilva","year":"2011","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.pcl.2015.03.005_bib58","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1186\/1465-9921-12-66","article-title":"Is sirolimus a therapeutic option for patients with progressive pulmonary lymphangioleiomyomatosis?","volume":"12","author":"Neurohr","year":"2011","journal-title":"Respir Res"},{"issue":"17","key":"10.1016\/j.pcl.2015.03.005_bib59","doi-asserted-by":"crossref","first-page":"1595","DOI":"10.1056\/NEJMoa1100391","article-title":"Efficacy and safety of sirolimus in lymphangioleiomyomatosis","volume":"364","author":"McCormack","year":"2011","journal-title":"N\u00a0Engl J Med"},{"issue":"6","key":"10.1016\/j.pcl.2015.03.005_bib60","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1016\/S2213-2600(13)70090-0","article-title":"Serum VEGF-D a concentration as a biomarker of lymphangioleiomyomatosis severity and treatment response: a prospective analysis of the Multicenter International Lymphangioleiomyomatosis Efficacy of Sirolimus (MILES) trial","volume":"1","author":"Young","year":"2013","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.pcl.2015.03.005_bib61","series-title":"Tuberous sclerosis complex: genes, clinical features, and therapeutics","first-page":"271","article-title":"Ophthalmic manifestations","author":"Agrawal","year":"2010"},{"issue":"10","key":"10.1016\/j.pcl.2015.03.005_bib62","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1001\/jamadermatol.2014.938","article-title":"Dermatologic and dental aspects of the 2012 International tuberous sclerosis complex consensus statements","volume":"150","author":"Teng","year":"2014","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.pcl.2015.03.005_bib63","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1111\/jdv.12665","article-title":"Analysis of current data on the use of topical rapamycin in the treatment of facial angiofibromas in tuberous sclerosis complex","volume":"29","author":"Balestri","year":"2015","journal-title":"J\u00a0Eur Acad Dermatol Venereol"},{"issue":"9","key":"10.1016\/j.pcl.2015.03.005_bib64","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1001\/jamadermatol.2014.87","article-title":"Successful treatment of subungual fibromas of tuberous sclerosis with topical rapamycin","volume":"150","author":"Muzic","year":"2014","journal-title":"JAMA Dermatol"}],"container-title":["Pediatric Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0031395515000255?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0031395515000255?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,23]],"date-time":"2018-09-23T14:56:01Z","timestamp":1537714561000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0031395515000255"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,6]]},"references-count":64,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2015,6]]}},"alternative-id":["S0031395515000255"],"URL":"https:\/\/doi.org\/10.1016\/j.pcl.2015.03.005","relation":{},"ISSN":["0031-3955"],"issn-type":[{"value":"0031-3955","type":"print"}],"subject":[],"published":{"date-parts":[[2015,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Tuberous Sclerosis Complex","name":"articletitle","label":"Article Title"},{"value":"Pediatric Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pcl.2015.03.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}